What is BPC-157?
A synthetic 15-amino-acid peptide whose sequence is described as a partial sequence of a protein found in human gastric juice.
US legal status
Open question
The Federal Register notice calls the HHS policy a "draft", with comments due by November 13, 2026, while the policy PDF is not labeled draft and RAPS describes it as in effect; no final or revised version was published as of November 16, 2026. State boards, such as Ohio's, may still restrict BPC-157.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
Reports to the FDA
- The FDA's adverse event database (FAERS, data to October 28, 2026) holds 24 reports that list "BPC-157", 21 of them flagged serious; the flags and the other drugs in the reports mean they do not show that BPC-157 caused the events. The most frequent terms are shortness of breath (dyspnoea), redness (erythema), headache and "drug ineffective" (3 each), then hypersensitivity, dizziness, nausea and flushing (2 each); the FDA's advisory committee review cited 3 FAERS cases, including shortness of breath, and darkened skin (hyperpigmentation) after a "research use only" blend of BPC-157 and another peptide.723
- FAERS (data through October 28, 2026) holds 26 reports in all: "BPC-157" and "BPC 157" each return the same 24, and "BPC157" returns 2.53
- The FDA's advisory committee review found three FAERS reports, all for injected BPC-157. One concerned a blend of BPC-157 and another peptide from Cellular Peptide LLC, labeled "research purposes only", and described darkened skin (hyperpigmentation) that came back when the product was taken again.33
What the FDA has said
- The FDA says BPC-157 "may pose risk for immunogenicity" (immune reactions) by some routes, and that its impurities and characterization are complex.4
- The FDA says it has "no, or only limited, safety-related information" for the proposed routes.4
- The HHS policy does not list a nasal route for BPC-157. The FDA has "strong concerns" about the nasal spray that was nominated, because nothing was known about its pump, container or closure, and says injected or nasal use "may pose a significant risk for immunogenicity"; no human nasal study exists.3161733
- In a footnote, the FDA explains that carcinogenicity studies are expected when a drug is used for 6 months or more of a person's life in total.33
- Angiogenesis (new blood vessel growth) appears in the FDA's text only as a hypothesized healing mechanism ("induce angiogenesis"); the FDA's written evaluation does not call it a tumor risk.3334
- The FDA says that as a 15-amino-acid peptide given by injection or nasal spray, BPC-157 "may pose a significant risk for immunogenicity."33
- The FDA's overall finding: "insufficient clinical safety information to characterize the safety profile."33
In studies and reviews
- The FDA said none of the human reports appears to describe serious adverse events, but the studies were short and small, used amounts "likely exploratory," and mostly did not make their safety monitoring clear.33
- In three standard genetic toxicity tests, BPC-157 free base did not cause mutations; the FDA relays the authors' conclusion "BPC-157 is not a mutagen."33
- In 28-day studies of injections into muscle in rats and dogs, the FDA found "clinically relevant safety signals": changes in clotting time (aPTT shorter in rats, longer in dogs) and liver-related signals (higher ALT, glucose and triglycerides). No longer studies exist.33
- Injections into muscle on days 6 to 15 of pregnancy in rats caused no fetal malformations. No study covers the full reproductive cycle.33
- Peer-reviewed authors raise a cancer question: a 2025 letter calls pro-angiogenic signaling a "plausible tumor-promoting hazard", and a 2026 Missouri Medicine review lists "pathological angiogenesis" and "carcinogenesis" among possible risks of unapproved peptides. These are hypotheses, not cases seen in people.1266
No data
- The FDA found no study that gave BPC-157 to people by mouth, under the skin, through the nose or through the skin.33
- A 2025 systematic review found "No clinical safety data". Side-effect data in animals cover at most 6 weeks, and the half-life in animals is under 30 minutes.11
- There are no data on pregnancy, breastfeeding, people under 18, people with a history of cancer, long-term use or repeated use; for the first five, we found no human data. One program excludes pregnancy, breastfeeding and under-18s, and flags a history of cancer.111226
- We found no published study in PubMed of how oral BPC-157 is absorbed, in animals or humans. The FDA says its pharmacokinetic profiles by mouth, rectally, under the skin, through the nose and through the skin "are unknown at this time," and that it "found no human pharmacokinetic data" by mouth, under the skin, through the nose or through the skin.333454
- The FDA found no carcinogenicity (cancer) studies of BPC-157, in its free base or acetate form.33
Product quality
- A 2026 preprint, not peer-reviewed, analyzed a voluntary third-party testing dataset of "research use only" peptides: 3.5% of BPC-157 reports failed identity (they did not contain the stated peptide), BPC-157 had one of the widest spreads of measured amount against the label (interquartile range 94% to 115%), and 15% of endotoxin-tested samples across all peptides had measurable endotoxin. The FDA found few certificates of analysis tested for impurities, aggregates or endotoxin, and found products sold under the name that contained different active moieties.152123
- Most BPC-157 certificates of analysis the FDA found "only contain purity testing results", with no impurity limits.33
- The FDA found nothing on bioburden, endotoxin or residual solvents for BPC-157 free base.33
- The FDA has seen "multiple salts, and derivatives, including different active moieties" sold under the name BPC-157.33
- A 2026 preprint, not peer-reviewed, counts 17 BPC-157 reports that did not contain the stated peptide.63
Compounded BPC-157 is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
The conditions of the HHS policy
The policy covers a compounded product only when all of its conditions are met.
- 1.Federal Register notice, FR Doc. 2026-22192, 91 FR 68526 (Oct 30, 2026), HHS OSTier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 2.HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug SubstancesTier 1: regulator or registerhhs.govread Nov 16, 2026↩
- 3.HHS policy Appendix B (identity and routes)Tier 1: regulator or registerhhs.govread Nov 16, 2026↩
- 4.FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of 04/22/2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 5.FDA Briefing Document, PCAC July 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 6.USADA: BPC-157 substance page (modified Aug 10, 2026)Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
- 7.openFDA FAERS API query "BPC-157" (data to 2026-10-28)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 8.eCFR 21 CFR Part 1308 (Schedules of controlled substances), as of 10/22/2026Tier 1: regulator or registerecfr.govread Nov 16, 2026↩
- 9.FDA Warning Letter, Peptide Partners LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 10.DoD Operation Supplement Safety: BPC-157 (Apr 29, 2025)Tier 1: regulator or registeropss.orgread Nov 16, 2026↩
- 11.Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025;21(4):485–495Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
- 12.Józwiak M et al. Reply to Sikiric et al. Pharmaceuticals 2025;18(10):1451Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
- 13.Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in interstitial cystitis: a pilot study. Altern Ther Health Med 2024 (PMID 39325560; abstract via UroToday)Tier 2: peer-reviewed or trial registryurotoday.comread Nov 16, 2026↩
- 14.NCT02637284 PCO-02 Safety and Pharmacokinetics Trial (registry mirror)Tier 2: peer-reviewed or trial registryctv.veeva.comread Nov 16, 2026
- 15.Mendias CL, Awan TM. Evaluation of Research Grade Peptides Marketed Directly to Consumers… Preprints 2026 (not peer-reviewed)Tier 2: peer-reviewed or trial registrypreprints.orgread Nov 16, 2026↩
- 16.Holland & Knight: HHS Issues Interim Enforcement Discretion Policy (Nov 4, 2026)Tier 3: reference, law firm or presshklaw.comread Nov 16, 2026↩
- 17.Venable: HHS Announces Interim Enforcement Discretion… (Nov 2026)Tier 3: reference, law firm or pressvenable.comread Nov 16, 2026↩
- 18.AJMC: 5 Things to Know About HHS's Interim Peptide Compounding Policy (Oct 29, 2026)Tier 3: reference, law firm or pressajmc.comread Nov 16, 2026↩
- 19.RAPS: HHS will permit compounding of six peptides ahead of formal rulemaking (Oct 29, 2026)Tier 3: reference, law firm or pressraps.orgread Nov 16, 2026↩
- 20.Orrick: FDA Announces Removal of 12 Peptides from Category 2 (Apr 2026)Tier 3: reference, law firm or pressorrick.comread Nov 16, 2026↩
- 21.Bass Berry & Sims: FDA Advisory Committee Recommends Six Peptides…Tier 3: reference, law firm or pressbassberry.comread Nov 16, 2026↩
- 22.FDA Law Blog (Hyman Phelps): PEPTIDE-L WAVE! PCAC Approves Four… (Jul 2026)Tier 3: reference, law firm or pressthefdalawblog.comread Nov 16, 2026↩
- 23.Drug Topics: FDA Panel to Evaluate 7 Popular Peptides (Jul 6, 2026)Tier 3: reference, law firm or pressdrugtopics.comread Nov 16, 2026↩
- 24.Arent Fox Schiff: RUO-ined: Five Peptide Vendors… (Aug 2026)Tier 3: reference, law firm or pressafslaw.comread Nov 16, 2026↩
- 25.Frier Levitt: Peptides Under the Microscope: FDA and State EnforcementTier 3: reference, law firm or pressfrierlevitt.comread Nov 16, 2026↩
- 26.HealthRX BPC-157 product pageTier 4: lead onlyhealthrx.comread Nov 16, 2026↩
- 27.Superpower Peptides pageTier 4: lead onlysuperpower.comread Nov 16, 2026↩
- 28.LiveVital homepage (no BPC-157 page found)Tier 4: lead onlylivevital.ioread Nov 16, 2026↩
- 29.Desert Mobile Medical BPC-157 product pageTier 4: lead onlydesertmobilemedical.comread Nov 16, 2026↩
- 30.FormBlends: Where to Buy BPC-157 OnlineTier 4: lead onlyformblends.comread Nov 16, 2026↩
- 31.PrimeLab (RUO vendor) BPC-157 10mgTier 4: lead onlyprimelab.us.comread Nov 16, 2026↩
- 32.Enos Labs USA (RUO vendor) Wolverine BPC/TB-500Tier 4: lead onlyenoslabsusa.comread Nov 16, 2026↩
- 33.FDA Briefing Document: Evaluation of BPC-157-Related Bulk Drug Substances (memo dated 5/11/2026), PCAC Jul 23–24, 2026Tier 1: regulator or registerFDA CDERread Nov 16, 2026↩
- 34.PCAC Jul 23, 2026: FDA PresentationsTier 1: regulator or registerFDAread Nov 16, 2026↩
- 35.July 23–24, 2026: Meeting of the PCAC (meeting page, content current 08/06/2026)Tier 1: regulator or registerFDAread Nov 16, 2026
- 36.Docket HHS-OASH-2026-0496 (documents, comments, docket record)Tier 1: regulator or registerregulations.gov / HHSread Nov 16, 2026↩
- 37.Federal Register API search: "peptide bulk drug substances", from 2026-07-01Tier 1: regulator or registerFederal Register (OFR/GPO)read Nov 16, 2026
- 38.Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (Jul 27, 2026)Tier 3: reference, law firm or pressMcDermott Will & Schulteread Nov 16, 2026↩
- 39.Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021;27(4):8–13. PMID 34324435Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026↩
- 40.Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025;31(5):20–24. PMID 40131143Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026↩
- 41.Poolton JT et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthop Belg 2026;92(3). PMID 42885452Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026↩
- 42.McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157. Curr Rev Musculoskelet Med 2025;18(12):611–619. PMID 40789979Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 43.Mateescu DM et al. BPC-157 as an Investigational Peptide Therapeutic. Pharmaceutics 2026;18(5):625. PMID 42198317Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 44.Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 2017;95(3):323–333. PMID 27847966Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 45.Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011;110(3):774–780. PMID 21030672Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 46.Chang CH et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 2014;19(11):19066–77. PMID 25415472Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 47.Hsieh MJ et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-eNOS pathway. Sci Rep 2020;10:17078. PMID 33051481Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 48.He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol 2022;13:1026182. PMID 36588717Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 49.Sikirić P et al. A new gastric juice peptide, BPC. J Physiol Paris 1993. PMID 8298609Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 50.Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017;9(10):1490–1498. PMID 28035768Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 51.Mazzarino M et al. Rapid and harmonized analytical workflow for doping agents in dried and liquid blood matrices. Analyst 2026;151(15):4398–4413. PMID 42328738Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 52.ClinicalTrials.gov API v2, query.term / query.intr "BPC-157"; records NCT02637284, NCT07437547, NCT07752381, NCT07803250Tier 1: regulator or registerNLM / ClinicalTrials.govread Nov 16, 2026↩
- 53.openFDA drug/event, BPC-157 name variants (counts by reaction, receivedate, seriousness, characterization)Tier 1: regulator or registerFDA openFDAread Nov 16, 2026↩
- 54.PubMed E-utilities esearch counts (queries as stated in 7b)Tier 1: regulator or registerNCBI / NLMread Nov 16, 2026↩
- 55.FDA Warning Letter: Predator Nutrition, MARCS-CMS 607136 (Oct 23, 2020)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 56.FDA Warning Letter: Prescription Dispensing Laboratories, Inc. dba PD Labs, 579286 (Jul 30, 2019)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 57.FDA Warning Letter: Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine, 615908 (Nov 10, 2021)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 58.FDA Warning Letter: Warrior Labz SARMs, 655280 (Jun 12, 2023)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 59.FDA untitled letter: Barclay, Luke, and Pillai Specialty Pharmacy, PLLC dba Meta Pharmacy Services (Sep 14, 2023)Tier 1: regulator or registerFDAread Nov 16, 2026↩
- 60.FDA Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted in the U.S. (revised 05/19/2026)Tier 1: regulator or registerFDA ORAread Nov 16, 2026
- 61.Ohio Board of Pharmacy: Ten Common Prescriber Clinic and Medical Spa Violations (updated 12/8/2025)Tier 1: regulator or registerOhio Board of Pharmacyread Nov 16, 2026↩
- 62.Louisiana Board of Pharmacy Bulletin 26-01: New Laws, 2026 Regular Session (Jul 10, 2026)Tier 1: regulator or registerLouisiana Board of Pharmacyread Nov 16, 2026↩
- 63.Mendias CL, Awan TM. Evaluation of Research Grade Peptides Marketed Directly to Consumers. Preprints 2026, 202604.1748 v1 (not peer-reviewed; abstract/index text only today)Tier 2: peer-reviewed or trial registryPreprints.orgread Nov 16, 2026↩
- 64.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026;56(8):1921–1935. PMID 41966639Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026
- 65.Tham A et al. Investigational Peptides in Orthopaedic Practice: BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg 2026 (online Oct 27). PMID 42937313Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026↩
- 66.Moiz A, O'Keefe EL, O'Keefe JH. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Mo Med 2026;123(4):337–343. PMID 42757290Tier 2: peer-reviewed or trial registryPubMedread Nov 16, 2026↩
- 67.Brennan, Manna & Diamond: Ohio Med Spas: Peptide Do's and Do Not's (Apr 29, 2026), pointer to S61Tier 3: reference, law firm or pressBrennan, Manna & Diamondread Nov 16, 2026
- 78.FDA: Bulk drug substances nominated for use in compounding under section 503A (Updated May 14, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 79.FDA: Bulk drug substances nominated for use in compounding under section 503B (Updated March 21, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 80.FDA warning letters database, full-text search "BPC-157" (2 results) and 2025–2026 letters under "peptide"Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 81.DEA: Controlled Substances, Alphabetical Order (Nov 12, 2026)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
- 82.USADA: Athlete Advisory: What's New on the 2027 WADA Prohibited List? (Oct 6, 2026)Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
- 83.Federal Register API: documents search "BPC-157", "peptide" compounding since 2026-10-30, docket HHS-OASH-2026-0496Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.